KRAS(G12C) Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

PURPOSE: KRAS(G12C) is the most common KRAS mutation in primary lung adenocarcinoma (LUAD). Phase I clinical trials have demonstrated encouraging clinical activity of KRAS(G12C) inhibitors in the metastatic setting. We investigated disease-free survival (DFS) and tumor genomic features in patients w...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Cancer Res
मुख्य लेखकों: Jones, Gregory D., Caso, Raul, Tan, Kay See, Mastrogiacomo, Brooke, Sanchez-Vega, Francisco, Liu, Yuan, Connolly, James G., Murciano-Goroff, Yonina R., Bott, Matthew J., Adusumilli, Prasad S., Molena, Daniela, Rocco, Gaetano, Rusch, Valerie W., Sihag, Smita, Misale, Sandra, Yaeger, Rona, Drilon, Alexander, Arbour, Kathryn C., Riely, Gregory J., Rosen, Neal, Lito, Piro, Zhang, Haiying, Lyden, David C., Rudin, Charles M., Jones, David R., Li, Bob T., Isbell, James M.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2021
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102372/
https://ncbi.nlm.nih.gov/pubmed/33593884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4772
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन